Related references
Note: Only part of the references are listed.Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
Roland B. Walter et al.
BLOOD (2013)
Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML
C. Ustun et al.
BONE MARROW TRANSPLANTATION (2013)
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
Francesco Buccisano et al.
BLOOD (2012)
Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia
Takuya Miyazaki et al.
LEUKEMIA RESEARCH (2012)
Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
Amy E. DeZern et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission
Steven E. McCormack et al.
LEUKEMIA RESEARCH (2011)
The role of multiparameter flow cytometry for disease monitoring in AML
Wolfgang Kern et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Effect of post- remission chemotherapy preceding allogeneic hematopoietic cell transplant in patients with acute myeloid leukemia in first remission
Lisa Sproat et al.
LEUKEMIA & LYMPHOMA (2010)
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies
Maria Diez-Campelo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry
Adhra Al-Mawali et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML)
Frederick R. Appelbaum
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2008)
Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia
Luca Maurillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
Martin Bornhaeuser et al.
BLOOD (2007)
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
F. Buccisano et al.
LEUKEMIA (2006)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
W Kern et al.
BLOOD (2004)
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification of fusion transcripts
S Schnittger et al.
BLOOD (2003)
Share Paper
